Skip to content

Interactive Session 1 – Hospital Pharmacists taking the lead in Orphan Drugs: supply chain, partnerships and technologies

Room:

Hall 1.61&1.62

Facilitator:

WED: De Rijdt, Thomas; THUR: Jenzer, Helena

Speakers:

Abstract:


Linked to EAHP Statements:
Section 1 – Introductory statements and governance
Section 2 – Selection, Procurement and Distribution

ACPE UAN: 0475-0000-16-021-L04-P. An application based activity.

Abstract

Rare diseases are life threatening or chronically debilitating, with a prevalence lower than 5 in 10 000 Europeans. For patients who suffer from rare diseases it isn’t uncommon to go for diagnosis and treatment in different EU-states due to the rarity of the condition.

Today more than 115 orphan drugs are authorised within all EU Member States for the diagnosis, prevention and treatment of rare diseases. Besides dispensing through the supply chain all pharmacy services for these patients need to be harmonized that focus on various aspects of the use of orphan drugs such as cost and reimbursement, adherence to (oral) medication, off-label and unlicensed use, compounding procedures, pharmacovigilance, companion diagnostics, adaptive pathways and home treatment.

New partnerships with patient organisations, small/medium sized enterprises and academia in the diagnosis, prevention and treatment of these patients will be discussed as well as new technologies such as advanced therapy medicinal products, hospital exemption, direct-to-consumer genetic testing, full genome newborn screening, public private partnership in drug development and cross border healthcare.

Teaching goals:
 
• To illustrate the new partnerships and technologies of orphan drugs in the diagnosis, prevention and treatment of patients with rare diseases;
• To define the responsibilities of the hospital pharmacists in the production and dispensing of new technologies such as advanced therapy medicinal products;
• To highlight the opportunities of the new partnerships for patients with (ultra)rare diseases;
• To demonstrate the necessity of a European platform for pharmacists with special interest in rare diseases.
 
Learning objectives

After the session, the participants should be able:
• to create best practices in the management of orphan drugs;
• to identify the clinical added value of orphan drugs in the diagnosis, prevention and treatment of rare diseases;
• to install clinical pharmacy services to patients with rare diseases.
 
Keywords: Rare diseases, Orphan drugs.
×

Deadline extended to July 15th

Problems caused by shortages are serious, threaten patient care and require urgent action.

Help us provide an overview of the scale of the problem, as well as insights into the impact on overall patient care.

Our aim is to investigate the causes of medicine and medical device shortages in the hospital setting,  while also gathering effective solutions and best practices implemented at local, regional, and national levels.

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.